Clinical Trial Update: Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated a combination therapy of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide in relapsed/refractory multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-04-21